



(51) International Patent Classification:

C12N 9/00 (2006.01) C12N 15/90 (2006.01)
C12N 15/63 (2006.01)

(21) International Application Number:

PCT/US2024/051582

(22) International Filing Date:

16 October 2024 (16.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/590,751 16 October 2023 (16.10.2023) US

(71) Applicants: TYPEWRITER THERAPEUTICS, INC.

[US/US]; c/o Bayer Co. Lab, 238 Main Street, Cambridge, Massachusetts 02142 (US). THE UNIVERSITY OF TOKYO [JP/JP]; 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo, 113-8654 (JP).

(72) Inventors: HEFFNER, Garrett; c/o Typewriter Therapeutics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US). ZHOU, Jun; c/o Typewriter Therapeutics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US). FUJIWARA, Haruhiko; c/o Typewriter Therapeutics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US).

tics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US). ENDO, Kei; c/o The University of Tokyo, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo, 113-8654 (JP).

(74) Agent: NIE, Alex; Sheppard Mullin Richter & Hampton, LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: R2 RETROTRANSPOSONS FOR GENE WRITING




FIG. 9

(57) Abstract: The present disclosure describes new R2 retrotransposons discovered from bird species. Two of them, from *Corvus moneduloides* (New Caledonian crow) and *Accipiter gentilis* (Eurasian goshawk) and referred to as R2Cm and R2Ag, respectively, exhibited excellent retrotransposition activities in human cells. These new retrotransposons, as well as engineered versions thereof, can be suitably used for targeted gene delivery.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*